B cells may have multiple roles in pathogenesis of CNS autoimmune disease. While data indicate that myelin-specific antibodies (Ab) promote demyelination in experimental autoimmune encephalomyelitis (EAE) and MS, the role of B cells in antigen (Ag) presentation in CNS autoimmune disease is not clear. When compared to other APC populations, B cells are efficient APC in presentation of protein Ag when they express the B cell receptor (BCR) specific for the Ag recognized by responding T cells. We hypothesize that B cells, in particular, myelin-specific B cells have an important role as APC in activation of myelin-specific T cells. We propose (1) to evaluate the contribution of myelin-specific B cells as APC in EAE and distinguish this function from the role of myelin-specific Ab in EAE. We are creating two transgenic (Tg) models, one containing B cells that express membrane MOG-specific BCR only, and one containing B cells that express membrane MOG-specific BCR and can secrete MOG-specific IgM. We will compare EAE susceptibility in these mice to B cell-deficient and MOG-specific BCR knock-in mice that can secrete all Ig isotypes. We propose (2) to examine the roles of B cell MHC II expression and myelin BCR specificity in presentation of myelin Ag in EAE. We hypothesize that B cells, in particular myelin-specific B cells, have a key role as APC in MHC II-restricted Ag presentation and activation of myelin-specific T cells in EAE and MS. (a) We will test the role of MHC II-restricted B cell Ag presentation to T cells by creating mixed bm chimera mice in which the B cell compartment is selectively deficient in MHC II expression, and compare activation of MOG-specific T cells and EAE susceptibility to bm chimera mice containing B cells that express MHC II molecules. (b) To clarify the role of BCR specificity in MHC II-restricted Ag presentation in EAE, we will examine mixed bm chimera mice in which B cells express either the MOG-specific BCR or nitrophenyl (NP)-specific BCR and do, or do not, express MHC II molecules. Recent clinical results suggest that anti-CD20 B cell depletion may be effective in MS treatment. Our preliminary data suggest that B cell depletion is beneficial in rMOG-induced EAE, but exacerbates MOG p35- 55-induced EAE. We hypothesize that the clinical benefit in rMOG-induced EAE results from reduced B cell Ag presentation or decreased secretion of myelin-specific Ab. We also hypothesize that exacerbation of MOG p35-55-induced EAE, a model that is less dependent upon B cells and Ab, represents loss of regulatory B cell function. In order to evaluate these possibilities, we will (3) examine how anti-CD20 B cell depletion influences MOG-specific T cell responses in the periphery and in the CNS in acute and chronic EAE, and examine whether MOG-specific Ab responses correlate with clinical improvement in anti-CD20 B cell-depleted mice. These studies should provide mechanistic insight regarding B cell depletion in CNS autoimmunity and address questions regarding B cell depletion that are not easily approached in MS clinical trials.

Public Health Relevance

B lymphocytes may have multiple roles in the pathogenesis of multiple sclerosis (MS), a central nervous system (CNS) autoimmune disease. Our studies in experimental autoimmune encephalomyelitis (EAE), the murine MS model, will evaluate and distinguish potentially pathogenic roles of B cells in CNS autoimmunity. Our research program will also evaluate how anti-CD20 B cell depletion, a therapeutic approach being investigated in MS clinical trials, may influence immune regulation. Page 5

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Esch, Thomas R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Cruz-Herranz, Andrés; Sagan, Sharon A; Sobel, Raymond A et al. (2017) T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury. J Nat Sci 3:
Sagan, Sharon A; Cruz-Herranz, Andrés; Spencer, Collin M et al. (2017) Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. J Vis Exp :
Lehmann-Horn, Klaus; Wang, Sheng-Zhi; Sagan, Sharon A et al. (2016) B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight 1:e87234
Schulze-Topphoff, Ulf; Varrin-Doyer, Michel; Pekarek, Kara et al. (2016) Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A 113:4777-82
Mowry, E M; Pelletier, D; Gao, Z et al. (2016) Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. Eur J Neurol 23:327-32
Sagan, Sharon A; Winger, Ryan C; Cruz-Herranz, Andrés et al. (2016) Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proc Natl Acad Sci U S A 113:14781-14786
Lehmann-Horn, Klaus; Sagan, Sharon A; Bernard, Claude C A et al. (2015) B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol 77:902-8
von Büdingen, H-Christian; Palanichamy, Arumugam; Lehmann-Horn, Klaus et al. (2015) Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol 73:238-46
Ryu, Jae Kyu; Petersen, Mark A; Murray, Sara G et al. (2015) Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun 6:8164
Onizawa, Michio; Oshima, Shigeru; Schulze-Topphoff, Ulf et al. (2015) The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol 16:618-27

Showing the most recent 10 out of 34 publications